Patents by Inventor Keigo Hanada

Keigo Hanada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190134094
    Abstract: The present invention relates to a method for producing en NKT cell ligand-pulsed human CD14 positive cell that activates NKT cells and strongly induces proliferation, IFN-? production, and/or cytotoxic activity of NKT cells. More specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and GM-CSF and substantially free of IL-4. In addition, the present invention relates to a method for producing an NKT cell ligand-pulsed human CD14 positive cell line and, specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and substantially free of GM-CSF and IL-4. The present invention also relates to a cell preparation containing an NKT cell ligand-pulsed human CD14 positive cell or an NKT cell ligand-pulsed human CD14 positive cell line and pharmaceutical use thereof.
    Type: Application
    Filed: April 14, 2017
    Publication date: May 9, 2019
    Applicants: RIKEN, AMBICION CO., LTD.
    Inventors: Masaru TANIGUCHI, Tomokuni SHIGEURA, Minako AIHARA, Keigo HANADA
  • Patent number: 8927493
    Abstract: An object of the present invention is to provide a drug for promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: January 6, 2015
    Assignee: Kringle Pharma, Inc.
    Inventors: Katsuro Tomita, Hiroyuki Tsuchiya, Katsuhiko Kitaoka, Junsuke Nakase, Keigo Hanada, Kunio Matsumoto
  • Patent number: 8518880
    Abstract: Disclosed is a therapeutic agent effective for the fundamental treatment of a spinal cord injury and a demyelinating disease. Specifically disclosed are a therapeutic agent for a spinal cord injury and a therapeutic agent for a demyelinating disease, each of which comprises an HGF protein as an active ingredient.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: August 27, 2013
    Assignees: Keio University, Osaka University, Kringle Pharma Inc.
    Inventors: Hideyuki Okano, Yoshiaki Toyama, Masaya Nakamura, Akio Iwanami, Kazuya Kitamura, Toshikazu Nakamura, Hiroshi Funakoshi, Keigo Hanada
  • Patent number: 8461112
    Abstract: The present invention relates to an HGF preparation comprising HGF and purified sucrose. The HGF preparation is characterized by being stable even after a long-term storage.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: June 11, 2013
    Assignee: Kringle Pharma Inc.
    Inventors: Kiichi Adachi, Keigo Hanada
  • Publication number: 20120021040
    Abstract: Disclosed is a therapeutic agent effective for the fundamental treatment of a spinal cord injury and a demyelinating disease. Specifically disclosed are a therapeutic agent for a spinal cord injury and a therapeutic agent for a demyelinating disease, each of which comprises an HGF protein as an active ingredient.
    Type: Application
    Filed: August 27, 2009
    Publication date: January 26, 2012
    Applicants: KEIO UNIVERSITY, KRINGLE PHARMA, INC., OSAKA UNIVERSITY
    Inventors: Hideyuki OKANO, Yoshiaki TOYAMA, Masaya NAKAMURA, Akio IWANAMI, Kazuya KITAMURA, Toshikazu NAKAMURA, Hiroshi FUNAKOSHI, Keigo HANADA
  • Publication number: 20110312887
    Abstract: An object of the present invention is to provide a drug for promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
    Type: Application
    Filed: October 8, 2009
    Publication date: December 22, 2011
    Applicant: KRINGLE PHARMA, INC.
    Inventors: Katsuro Tomita, Hiroyuki Tsuchiya, Katsuhiko Kitaoka, Junsuke Nakase, Keigo Hanada, Kunio Matsumoto
  • Publication number: 20100081617
    Abstract: Disclosed is a therapeutic agent effective for the fundamental treatment of a spinal cord injury and a demyelinating disease. Specifically disclosed are a therapeutic agent for a spinal cord injury and a therapeutic agent for a demyelinating disease, each of which comprises an HGF protein as an active ingredient.
    Type: Application
    Filed: August 27, 2009
    Publication date: April 1, 2010
    Applicants: KEIO UNIVERSITY, OSAKA UNIVERSITY, KRINGLE PHARMA, INC.
    Inventors: Hideyuki OKANO, Yoshiaki TOYAMA, Masaya NAKAMURA, Akio IWANAMI, Kazuya KITAMURA, Toshikazu NAKAMURA, Hiroshi FUNAKOSHI, Keigo HANADA
  • Publication number: 20090233863
    Abstract: The present invention relates to an HGF preparation comprising HGF and purified sucrose. The HGF preparation is characterized by being stable even after a long-term storage.
    Type: Application
    Filed: April 29, 2009
    Publication date: September 17, 2009
    Applicant: KRINGLE PHARMA, INC.
    Inventors: Kiichi Adachi, Keigo Hanada
  • Publication number: 20060128737
    Abstract: The present invention provides nonsteroidal tetrahydroquinoline derivatives of general formula (I) or salts thereof: (R1, R2, X, Y, Z and m are as defined in claim 1) which show no excessive action on the prostate but show a particularly potent androgen receptor agonistic action on skeletal muscle tissue and bone tissue, as well as pharmaceuticals comprising such derivatives or their salts as active ingredients.
    Type: Application
    Filed: June 19, 2003
    Publication date: June 15, 2006
    Applicant: KAKEN PHARMACEUTICAL CO., LTD.
    Inventors: Motonori Miyakawa, Yuji Sumita, Kazuyuki Furuya, Kiyonoshin Ichikawa, Noriko Yamamoto, Seiji Amano, Hiroaki Nejishima, Keigo Hanada
  • Patent number: 7037919
    Abstract: Tetrahydroquinoline derivatives of general formula (I) or salts thereof, having a specific and strong binding affinity for AR and exhibiting AR agonism or antagonism; and pharmaceutical compositions containing the derivatives or the salts.
    Type: Grant
    Filed: October 6, 2000
    Date of Patent: May 2, 2006
    Assignee: Kaken Pharmaceutical Co. Ltd.
    Inventors: Keigo Hanada, Kazuyuki Furuya, Kiyoshi Inoguchi, Motonori Miyakawa, Naoya Nagata
  • Patent number: 6833354
    Abstract: An object of the present invention is to provide a novel agent for the treatment of bone diseases which can shorten a period for curing various fractures including acceleration of bone formation for bone defect, can improve bone strength of united bones and can also improve reduced bone strength accompanied by various diseases. The agent comprises as an effective ingredient a basic fibroblast growth factor and/or its analogue.
    Type: Grant
    Filed: February 17, 1994
    Date of Patent: December 21, 2004
    Assignee: Kaken Pharmaceutical Co., Ltd.
    Inventors: Keigo Hanada, Yoshiyuki Hiyama, Makoto Tamura
  • Patent number: 6777427
    Abstract: Tetrahydroquinoline compounds of general formula (I) or pharmacologically acceptable salts thereof, which have a specific and strong binding affinity for AR, exhibit AR agonism or antagonism, have therapeutic effects on AR-mediated diseases, particularly by not acting excessively on the prostate as AR agonists, but by showing potent action on skeletal muscle tissue and bone tissue; and pharmaceutical compositions comprising the compounds or the salts as active ingredients:
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: August 17, 2004
    Assignee: Kaken Pharmaceutical Co., Ltd.
    Inventors: Motonori Miyakawa, Seiji Amano, Misa Kamei, Keigo Hanada, Kazuyuki Furuya, Noriko Yamamoto
  • Publication number: 20030216428
    Abstract: Tetrahydroquinoline compounds of general formula (I) or pharmacologically acceptable salts thereof, which have a specific and strong binding affinity for AR, exhibit AR agonism or antagonism, have therapeutic effects on AR-mediated diseases, particularly by not acting excessively on the prostate as AR agonists, but by showing potent action on skeletal muscle tissue and bone tissue; and pharmaceutical compositions comprising the compounds or the salts as active ingredients: 1
    Type: Application
    Filed: March 13, 2003
    Publication date: November 20, 2003
    Inventors: Motonori Miyakawa, Seiji Amano, Misa Kamei, Keigo Hanada, Kazuyuki Furuya, Noriko Yamamoto
  • Patent number: 5350743
    Abstract: A bisphosphonic acid derivative of the formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein A is ##STR2## each of R.sup.3 and R.sup.4, which may be the same or different, is (i) a hydrogen atom, (ii) a C.sub.1-6 alkyl group, a C.sub.2-6 alkenyl group, a C.sub.2-6 alkynyl group, a C.sub.1-6 alkyl-carbonyl group, a C.sub.2-6 alkenyl-carbonyl group, a C.sub.2-6 alkynyl-carbonyl group R.sup.5 and R.sup.6, which may be the same or different, is a hydrogen atom, a hydroxyl group, a halogen atom, a cyano group, a carbamoyl group, an aralkyl group, a substituted or unsubstituted phenyl group, a substituted or unsubstituted amino group, a C.sub.1-6 alkyl group, a C.sub.2-6 alkenyl group, a C.sub.2-6 alkynyl group;each of m and n is 0 or a positive integer, provided that (m+n) is from 2 to 5; andR is a hydrogen atom, a C.sub.1-8 alkyl group or a C.sub.7-15 aralkyl group.
    Type: Grant
    Filed: February 6, 1992
    Date of Patent: September 27, 1994
    Assignee: Kaken Pharmaceutical Co., Ltd.
    Inventors: Yoshitaka Ohishi, Makoto Tamura, Mitsuo Hayashida, Satoru Ikegami, Yoshiyuki Hiyama, Takao Awa, Kiyonoshin Ichikawa, Kiyoshi Nomiyama, Keigo Hanada, Mitsuo Mimura